Replies to post #250118 on Biotech Values

[DewDiligence]

GPCR—is it down more for it's Diabetes effect than its Weight loss aspect?

IMO, the impetus for today’s selloff is the modest weight loss in both the T2D cohort (3-4% at 12 wks) and the obesity cohort (4.7% at 8 wks, placebo-adjusted).